Proteomic research in renal transplantation

Research output: Contribution to journalArticle

Abstract

Expression proteomics is a valuable tool for biomarker discovery. Currently there is a great deal of interest in the development of urine biomarkers for detection of renal allograft rejection as an alternative to percutaneous needle biopsy, which is the "gold standard." Needle biopsy is costly and associated with significant patient morbidity and mortality. This review will discuss the author's current work in proteomics-based urine biomarker discovery, as well as alternative approaches used by other groups that use SELDI mass spectrometry. The current state of urine transplant biomarkers will be discussed, and in conclusion there will be a brief discussion of how urine biomarkers will be used for transplant patient management once they are validated and analyte-specific assays are developed.

Original languageEnglish (US)
Pages (from-to)19-22
Number of pages4
JournalTherapeutic Drug Monitoring
Volume28
Issue number1
DOIs
StatePublished - Feb 2006

Fingerprint

Biomarkers
Proteomics
Kidney Transplantation
Urine
Transplants
Research
Biopsy
Needle Biopsy
Needles
Allografts
Mass spectrometry
Assays
Mass Spectrometry
Morbidity
Kidney
Mortality

Keywords

  • Renal allograft rejection
  • SELDI
  • Urine biomarkers
  • Urine proteomics

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Proteomic research in renal transplantation. / Clarke, William.

In: Therapeutic Drug Monitoring, Vol. 28, No. 1, 02.2006, p. 19-22.

Research output: Contribution to journalArticle

@article{32022ca0a84549679caed489bdcc316e,
title = "Proteomic research in renal transplantation",
abstract = "Expression proteomics is a valuable tool for biomarker discovery. Currently there is a great deal of interest in the development of urine biomarkers for detection of renal allograft rejection as an alternative to percutaneous needle biopsy, which is the {"}gold standard.{"} Needle biopsy is costly and associated with significant patient morbidity and mortality. This review will discuss the author's current work in proteomics-based urine biomarker discovery, as well as alternative approaches used by other groups that use SELDI mass spectrometry. The current state of urine transplant biomarkers will be discussed, and in conclusion there will be a brief discussion of how urine biomarkers will be used for transplant patient management once they are validated and analyte-specific assays are developed.",
keywords = "Renal allograft rejection, SELDI, Urine biomarkers, Urine proteomics",
author = "William Clarke",
year = "2006",
month = "2",
doi = "10.1097/01.ftd.0000194500.40021.37",
language = "English (US)",
volume = "28",
pages = "19--22",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Proteomic research in renal transplantation

AU - Clarke, William

PY - 2006/2

Y1 - 2006/2

N2 - Expression proteomics is a valuable tool for biomarker discovery. Currently there is a great deal of interest in the development of urine biomarkers for detection of renal allograft rejection as an alternative to percutaneous needle biopsy, which is the "gold standard." Needle biopsy is costly and associated with significant patient morbidity and mortality. This review will discuss the author's current work in proteomics-based urine biomarker discovery, as well as alternative approaches used by other groups that use SELDI mass spectrometry. The current state of urine transplant biomarkers will be discussed, and in conclusion there will be a brief discussion of how urine biomarkers will be used for transplant patient management once they are validated and analyte-specific assays are developed.

AB - Expression proteomics is a valuable tool for biomarker discovery. Currently there is a great deal of interest in the development of urine biomarkers for detection of renal allograft rejection as an alternative to percutaneous needle biopsy, which is the "gold standard." Needle biopsy is costly and associated with significant patient morbidity and mortality. This review will discuss the author's current work in proteomics-based urine biomarker discovery, as well as alternative approaches used by other groups that use SELDI mass spectrometry. The current state of urine transplant biomarkers will be discussed, and in conclusion there will be a brief discussion of how urine biomarkers will be used for transplant patient management once they are validated and analyte-specific assays are developed.

KW - Renal allograft rejection

KW - SELDI

KW - Urine biomarkers

KW - Urine proteomics

UR - http://www.scopus.com/inward/record.url?scp=33745504163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745504163&partnerID=8YFLogxK

U2 - 10.1097/01.ftd.0000194500.40021.37

DO - 10.1097/01.ftd.0000194500.40021.37

M3 - Article

C2 - 16418688

AN - SCOPUS:33745504163

VL - 28

SP - 19

EP - 22

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -